"ALL ANTIDEPRESSANTS ARE CREATED EQUAL"
(SOME ARE MORE EQUAL THAN OTHERS)

"All antidepressants have a 60-70% response rate". "Nobody has ever proved that one antidepressant is better than another".

How far are these statements true? Does this mean that antidepressants are interchangeable?

All marketable drugs are categorized as belonging to a particular class depending upon specific biochemical or pharmacological properties. Grouping together drugs in this fashion has certain advantages and disadvantages.

To assume that drugs belonging to a particular class can be used interchangeably may not be true. Interchangeability does not take into account the benefit, risk or cost of the drug. Drug selection within a class may depend on marketing strategies (Furberg et al., 1999).

Drug regulating agencies assume that all drugs within a class are related by structure, activity or adverse effects. This assumption is qualitative i.e., whether the drug is effective when compared to standard drug or placebo. The agency is not concerned with quantitative differences in terms of efficacy or safety. It is the marketing department, which often decides this issue. Certain drugs may have long term side effects, which become obvious only by post marketing surveillance or anecdotal reports by practitioners (pharmacovigilance).

Why should an antidepressant be changed?

The three main reasons are lack of efficacy, troublesome side effects, or the high cost of the drug.

Traditionally, antidepressants are classified into three groups viz., tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAOIs).

Drugs belonging to a particular group are supposedly interchangeable. But there are limitations.

Dothiepin, doxepin and amitriptyline are all sedative tricyclic antidepressants. If a switchover is made from dothiepin to doxepin or amitriptyline for some reason, there is a risk of developing acute urinary retention, or frequent falls and fractures because of marked anticholinergic and adrennergic side effects with amitriptyline and doxepin which can be disastrous (Kaplan & Sadock, 1991).

When changing over from a TCA to an SSRI, the SSRI may not prove as effective as the TCA (Preskorn, 1994). TCAs are more effective than SSRIs, especially in severely depressed inpatients (DUAG, 1988; DUAG, 1990; Roose et al., 1994; Anderson & Tomenson, 1994). Simultaneous administration of a TCA and a SSRI can increase the TCA levels and cause severe side effects like seizures or cardiotoxicity or a serotonergic syndrome during the change over period (Montgomery, 1998).

In comparative drug trials between two drugs, the statistical conclusion "no significant difference between two groups" does not mean the two drugs are equally effective. At periodic follow-up assessments during the trial, a patient on drug 'A' may say "Doctor I feel great, can I stop the pills?" In contrast, the patient on drug 'B' may say "Doctor, like that, I am alright, but-----". This could mean that drug 'B' is probably not as effective as drug 'A'. The two drugs may be quantitatively different though statistically not different. Statistical significance is not the same thing as clinical efficacy. Inadequate recovery
or residual symptoms of depression after antidepressant treatment, is one of the chief reasons for treatment resistant depression and relapses.

Approximately 20% of patients on antidepressant treatment will develop side effects of which about 90% will become treatment resistant if the same antidepressant is continued. TCAs are more liable to produce side effects than SSRIs because of action on multiple receptor systems. SSRIs act predominately on a single receptor system. A single dose of a TCA can produce pharmacological effects similar to a "cocktail" of various drugs. For instance, a 25 mg dose of amitriptyline can produce effects as if a combination of chlorpheniramine, benzodiazepine, desipramine, sertraline, cimetidine, prazosin and quinidine had been administered (Preskorn, 1994). However it is naive to assume that a SSRI will have effect on the serotonin system alone. It is not possible to modulate the serotonin system without modulating the norepinephrine system also, because of their anatomical and physiological proximity (Richelson, 1994). So SSRIs also have their own side effects. But they are a different set of side effects.

In the present state of knowledge, antidepressants can be continued indefinitely (Herschfield, 1994). If there is a long-term side effect e.g., tardive dyskinesia which can occur with amoxapine, a change over may be required (Hsin-Tung et al., 2000). An SSRI would then be the antidepressant of choice because of minimal long-term side effects. SSRIs especially fluoxetine can interfere with cytochrome enzyme P450 which is involved in the metabolism of several drugs (De Vane, 1994). The long term consequences of prolonged interference with cytochrome enzyme P450 are not known (Preskorn, 1994).

Medically compromised patients with depression are preferably treated with a SSRI because of the mild degree of depression and the minimal risk of side effects. Most of these patients are on polypharmacy. Concurrent SSRI administration can create problems because of drug interactions, which would not be the case with TCAs (Preskorn, 1994).

With some SSRIs, prolonged administration may worsen the depressive symptoms through sensitization (Fava, 1999) or induce tolerance requiring higher doses of the drug to produce the same effect (Lieb, 1984) (a form of tachyphylaxis). Conversely, some TCAs may show therapeutic effects only after prolonged administration. This becomes relevant at time of switching over from one class of drugs to another.

It may be necessary to change over from an expensive antidepressant to less expensive one for economic reasons. In the long term the new drug may not be cost effective because of hidden expenses which were not apparent initially. The drug may have a delayed onset of action, may require several daily doses, may need constant monitoring or expensive investigations, may be difficult to obtain, or have high overdosage toxicity etc. The purchase price of the drug is by no means the only criterion for overall cost effectiveness.

Therefore, antidepressants should not be interchanged indiscriminately unless there are solid reasons like health benefit and long term safety. Most people are reluctant to change their barbers, their dentists or their spouses. The same caution should be exercised when changing antidepressants.

Dinshaw R. Doongaji

REFERENCES

Anderson, I.M. & Tomenson, B.M. (1994) The efficacy of selective serotonin reuptake inhibitors in depression: a meta analysis of studies against tricyclic antidepressants. J Psychopharmacol. 8, 238-249

Danish University Antidepressant Group (1988) Citalopram clinical effect profile in comparison with clomipramine. A controlled multicentric study. J Psychopharmacol. 10, 131-138
At Lundbeck we believe the treatment of psychiatric disorders should restore, not restrict.
We help to renew people's lives, giving them the confidence, the energy, and the inspiration to thrive.

Lundbeck
Specialists in psychiatry, pioneers in neurology
Your patient-friendly antidepressant

Once Daily AM or PM

Serlift 50
Serlift 100

Lifts depression, improves quality of life

Superior features, better results

• Superior potency when compared to amitriptyline and fluoxetine
• Reduced incidences of common cardiovascular and anticholinergic side effects
• Negligible effect on body weight and sedation
• Indicated in depression with or without anxiety, OCD and panic disorders

Ensures

Active days, restful nights

with a simple dose without a doze

For further information contact:

Solus Pharmaceuticals Ltd.
(A RANBAXY Group Company)
Plot No. 114, Street 15, MIDC, Andheri (E), Mumbai-400 093
Prothiaden 75

(Dothiepin HCl - 75mg)

Established antidepressant efficacy
Quick relief from anxiety
Prompt onset of action
Improves sleep pattern and daytime alertness
Extremely well tolerated
Convenient single evening dose

Available in India and U.K.

*For full prescribing information, write to Lenbrook Pharmaceuticals Ltd (a subsidiary of Knoll Pharmaceuticals Ltd)
Unit No. 3-4 Corporate Park
Sion-Thane Road Mumbai 400 071
Zosert
Sertraline 25 / 50 / 100 mg

Turns Depressive blues to joy and cheer

- Depression
- Anxiety associated with depression
- OCD
- Panic disorder

Lets the Sun shine safely in
MARC I

ESTABLISHES YET ANOTHER LANDMARK
IN THE FIELD OF
EPILEPSIES & CONVULSIVE DISORDERS
INCLUDING
DEPRESSIVE SYNDROME

INTRODUCING:

**FOBIGONE** TABLET (100/200/400 mg) & SYRUP (100 mg/5.0 ml) OF CARBAMAZEPINE

**ALZONEX** TABLET (0.25/0.50/1.0 mg) OF ALPRAZOLAM

**CLONAXYL** TABLET (0.5 mg/2.0 mg) OF CLONAZEPAM

**SODAVAL** TABLETS (200 mg/500 mg,) & SYRUP (200 mg/5 ml) OF SODIUM VALPROATE EFFECTIVELY

**CALVIT**: SYRUP, TABLET & INJECTION

| CALVIT Syrup | CALVIT Tablet | CALVIT Injection |
|--------------|---------------|-----------------|
| Each 5 ml. Contains | Each Tablet Contains | Each 1 ml. Contains |
| Calcium Gluconate 200 gm. | Calcium Carbonate 1000 mg | Calcium Gluconolactobionate 137.5 mg |
| Ferric Ammonium Citrate 45 mg | Equivalent to Calcium 400 mg | Cholecalciferol 5000 I.U. |
| Proteolysed Liver extract 1.65 mg | Vit D₃ 200 I.U. | Vit B₁₂ 50 mcg |
| Cholecalciferol 400 I.U. | | Benzyl Alcohol 1.5% w/v |
| Vit B₁₂ 3.5 mcg | CHEWABLE TAB. | Water of inj. Q.S. |
| Sorbitol Base | Mint Flavour | |

MARC LABORATORIES PVT. LTD.
78 L.D.C. MEHRAULI ROAD,
GURGAON

Email marclab@lw1.vsnl.net.in
marclab@satyam.net.in
PROXAR (CIPRO.-100/500/750)
RAZOL (ALPRAZOLAM TAB.)
AXULES (HEMATINIC-CAP./SYP.)
AXULES PLUS (IRON + CAL. + VIT. D₃)
ZNG (POWDER OF DEXTROSE+FRUCTOSE + VIT. C+ZINC)
FLUTEX (FLUOXETINE)
NORAX–PB (NORFLOXACIN + TINIDAZOLE)
VITABEE (B-COMPLEX-CAP/SYP)
MEDICATRIC (GINSENG+SHILAJEET CAPS)
SHALTONE (MULTI VITAMINS-SYP / DROPS)
ZYMAN (ENZYME-SYP)
AXABAND (ALBENDAZOLE TAB)
GEEZOX (DICLOF SOD.+PARA+CHLORZOXAZONE)

AXAR PHARMACEUTICALS
MUZMUVDA, BARODA-390 020.
Give someone with epilepsy a future to look forward to

**VALPARIN**
(Sodium Valproate)
The first line broad spectrum antiepileptic

Help Parkinson’s patients enjoy better quality of life with...

**TIDOMET**
(Carbidopa + Levodopa)
The treatment of choice in Parkinson’s Therapy

**JUMEX**
(Selegiline HCl)
Smoothes the way for the patient of Parkinson’s Disease

with best compliments from:
SANOFI TORRENT (INDIA) Ltd.
GANDHI MANSION, 20 ALTAMOUNT ROAD, MUMBAI - 400 026.
TEL: (91-22) 389 6734-36, FAX: (91-22) 380 2967
The face of depression now gets a triple lift

ZERT-ODA
Sertraline 50/100mg tablets

Cognition
Balance
Affect
Conation

Effective management of depression

For further information contact:

MPG Life Sciences Limited
483, Cest Mael, Dr. A. B. Road, Worli, Mumbai 400 025.

or visit us at www.rpgls.com/doctors
EDITORIAL: ALL ANTIDEPRESSANTS ARE CREATED EQUAL

Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibition showing better tolerance but weaker efficacy than clomipramine and controlled multicentric study. J. Affect. Dis., 188, 289-299.

De Vane Lindsay, C. (1994) Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Cl. Psychiat., 55, (Suppl.12), 38-45.

Fava Giovanni, A. (1999) Potential sensitizing effects of antidepressant drugs in depression. CNS Drug, 247-256.

Furberg Curt, D., Herrington David, M. & Psaty Bruce, M. (1999) Are drugs within a class interchangeable. Lancet, 154, 1202-1204.

Hirschfield Robert, I.M. (1994) Guidelines for the long term treatment of depression. J. Cl. Psychiat., 55, (Suppl.12), 69.

Hsin-Tung Edmond & Simpson George, M. (2000) Medication induced movement disorders. in Kaplan and Sadock's Comprehensive Text Book of Psychiatry. (Eds.) Sadock, B.J. & Sadock, V.A., 2265.

Kaplan, H.I. & Sadock, B.J. (1976) Pocket Handbook of Psychiatric Drug Treatment. 174. New Delhi B J. Waverly Pvt. Ltd.

Lieb, J. & Balter, A. (1984) Antidepressant tachyphylaxis. Med. Hypotheses. 15, 279-291.

Montgomery Stewart, A. (1998) Psychopharmacology of obsessive compulsive disorder. CNS Spectrum, 3, (Suppl.5), 33.

Preskorn Sheldon, H. (1994) Antidepressant drug selection. Criteria and options. J. Cl. Psychiat., 55, (Suppl 9A), 9, 14 & 23.

Preskorn Sheldon, H. (1994) Update on antidepressant therapy. J. Cl. Psychiat., 55, (Suppl 9A), 5.

Richelson, E. (1994) Discussion. The pharmacology of antidepressants at the synapse. Focus on newer compounds. J. Cl. Psychiat., 55, (Suppl.9A), 40.

Roose, S.P., Glassman, A.H., Attila, E. & Woodring, S. (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Amer. J. Psychiatry, 151, 1735-1739.

DINSHAW R. DOC NGAJII MD, DPM (Bom), MS(Minn), FRSM, FRCPsych (Lond), FACP (Hon). FAPA (Corr.), FAMS, (Retd.) Hon Prof & Head, Dept. of Psychiatry, Hon. Associate, Dept. of Clinical Pharmacology, K.E.M. Hospital and G.S. Medical College, Bombay. (*1st Floor 14. Aderbad Apartments, 34. Huges Road, Bombay-400 007)